Epizyme Reports Data From Phase 1 Study Of EZH2 Inhibitor EPZ-6438 - Quick Facts

(RTTNews) - Epizyme, Inc. (EPZM), in conjunction with its development partner Eisai, announced that clinical data from the ongoing Phase 1 study of EPZ-6438 (E7438), an oral, small molecule inhibitor of EZH2, would be featured in a late-breaking oral presentation at the 26th EORTC-AACR-NCI Symposium on Molecular Targets and Cancer Therapeutics, to be held November 18-21 in Barcelona, Spain.

The presentation woud take place during the plenary session on Epigenetic Targets. Moreover, this session would feature a presentation from Chief Scientific Officer Robert Copeland, Ph.D., discussing Epizyme's targeted therapies against the histone methyltransferases (HMTs) DOT1L and EZH2.